MedTrace Logo

Ph II Study of Perifosine Plus Gleevec for Patients With GIST

NCT00455559 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-02-22

No results posted yet for this study

Summary

This is a Phase II trial designed to determine the efficacy and safety of perifosine plus imatinib mesylate in patients with advanced GIST who develop progressive disease or recurrence while receiving imatinib mesylate.

Conditions

Interventions

DRUG

Perifosine

DRUG

Imatinib Mesylate

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    collaborator OTHER

  • AEterna Zentaris

    lead INDUSTRY

Principal Investigators

  • Jonathan Trent, MD, PhD · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2010-11-30
Completion
2011-10-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00455559 on ClinicalTrials.gov